| Study # | Series # | Study reference | Type of subjects (BP status) | VPP/IPP dose (mg/d)b | VPP/IPP dose InVPP eq. (mg/d)c |
| Treated group |
|
| Placebo group |
| Effect-size |
|
| n | Change in SBP (mmHg) |
| n | Change in SBP (mmHg) |
| Mean difference between groups (mmHg) | SE | ||||||
|
| Mean | SD |
| Mean | SD |
|
| ||||||
| 1 | 101 | Aihara 2005 [30] | PHT | 13 | 16 | 20 | NA | NA | 20 | NA | NA | −3.2 | 2.8 |
| 2 | 201 | Ishida 2006 [34] | PHT | 16 | 23 | 9 | −8.3 | 10.0 | 9 | −3.9 | 9.6 | −4.4 | 4.6 |
| 2 | 202 | Ishida 2006 [34] | NT | 16 | 23 | 9 | −0.7 | 8.6 | 9 | −1.3 | 13.6 | 0.6 | 5.4 |
| 3 | 301 | Ishida 2007 [35] | PHT | 4 | 5 | 35 | −6.8 | 8.4 | 36 | −3.2 | 7.5 | −3.6 | 1.6 |
| 4 | 401 | Ishida 2011 [31] | NT | 17 | 24 | 8 | −2.5 | 5.6 | 8 | 2.4 | 4.7 | −4.9 | 2.6 |
| 4 | 402 | Ishida 2011 [31] | PHT | 17 | 24 | 8 | −6.7 | 8.1 | 8 | −1.9 | 4.8 | −4.8 | 3.3 |
| 5 | 501 | Itakura 2001 [36] | NT | 3 | 3 | 13 | −3.3 | 5.3 | 13 | 0.7 | 5.6 | −4.0 | 2.1 |
| 6 | 601 | Mizuno 2005 [32] | PHT | 4 | 5 | 12 | −2.8 | 5.8 | 12 | 0.3 | 7.4 | −3.1 | 2.7 |
| 6 | 602 | Mizuno 2005 [32] | PHT | 3 | 3 | 12 | −1.5 | 7.8 | 12 | 0.3 | 7.4 | −1.8 | 3.1 |
| 6 | 603 | Mizuno 2005 [32] | PHT | 2 | 2 | 12 | −1.5 | 10.4 | 12 | 0.3 | 7.4 | −1.8 | 3.7 |
| 7 | 701 | Nakamura 2004 [38] | PHT | 4 | 5 | 53 | −6.1 | 5.7 | 53 | −2.1 | 8.4 | −4.0 | 1.3 |
| 8 | 801 | Sano 2005 [33] | PHT | 3 | 4 | 52 | −4.6 | 6.2 | 52 | −1.7 | 6.2 | −2.9 | 1.1 |
| 9 | 901 | Sano 2004 [39] | NT | 9 | 13 | 6 | 0.8 | 4.4 | 5 | 0.3 | 10.8 | 0.5 | 4.8 |
| 9 | 902 | Sano 2004 [39] | PHT | 9 | 13 | 8 | −4.4 | 6.9 | 8 | 1.4 | 5.3 | −5.8 | 3.1 |
| 10 | 1001 | Kajimoto 2001 [37] | NT | 12 | 16 | 21 | −3.9 | 7.9 | 22 | −0.9 | 11.2 | −3.0 | 3.0 |
| 11 | 1101 | Uchida 2016 [40] | PHT | 3 | 5 | 11 | −4.0 | 14.0 | 13 | −2.2 | 16.5 | −1.8 | 6.3 |
| 11 | 1102 | Uchida 2016 [40] | NT | 3 | 5 | 15 | 1.7 | 11.3 | 9 | 7.2 | 12.7 | −5.5 | 5.0 |